A Study of the ApricityCare Program for Early Detection and Management of Treatment-Related Adverse Events in Patients With Cancer
M.D. Anderson Cancer Center
425 participants
Dec 18, 2024
INTERVENTIONAL
Conditions
Summary
To evaluate the rate of therapy discontinuation due to toxicity (side effects) among participants with cancer using ApricityCare. Investigators want to learn if identification of early clinical signs of irAEs with timely treatment can prevent severity progression and reduce treatment discontinuation.
Eligibility
Inclusion Criteria8
- Age 18 years of age or older
- Confirmed diagnosis of cancer
- Part 1 (Run-in Phase): Only patients with prostate, kidney, and/or bladder cancer will be enrolled with either localized or metastatic disease.
- Part 2 (Expansion Phase): Metastatic patients will be enrolled. Note, evaluable metastatic patients from Ppart 1 will be counted in Cohort A as described in section 8.4.
- Planned to receive systemic anti-cancer therapy
- Ability to understand and the willingness to sign a written informed consent document
- Ability to speak, read, and understand one of the following languages: English, Spanish, Mandarin and Cantonese Chinese
- Ownership of a smartphone and willingness to use it as outlined by the protocol and described in the ICF
Exclusion Criteria1
- \- Have any medical, psychological, or social condition that, in the opinion of the investigator would preclude participation in this study (pregnancy is not exclusionary and pregnant women will be permitted to enroll in the study).
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Participants will be asked to to take part in a research study because you have metastatic cancer (meaning that your cancer has spread to other parts of the body) and will be starting systemic therapy.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06693687